Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Satsuma citrus polysaccharide is a bioactive carbohydrate polymer extracted from the pulp of the Satsuma mandarin (*Citrus unshiu*). It is primarily investigated for its therapeutic potential in inflammatory bowel diseases, specifically ulcerative colitis. The compound functions as a prebiotic and anti-inflammatory agent that restores intestinal barrier integrity and balances gut microbiota. In preclinical models, it has been shown to selectively enrich beneficial bacteria such as *Lachnospiraceae_NK4A136_group* and promote the production of short-chain fatty acids (SCFAs), including propionate and butyrate. These metabolic changes contribute to the reinforcement of the physical gut barrier by up-regulating tight junction proteins like ZO-1 and Occludin, as well as Mucin-2 (MUC2). Additionally, it helps suppress pro-inflammatory cytokines such as TNF-α and IL-6 while enhancing anti-inflammatory markers like IL-10.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on satsuma citrus polysaccharide.